Stem cells of the islets of langerhans and their use in treating diabetes mellitus
View Patent ↗Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
1. A population of nestin-positive human pancreatic stem cells wherein said nestin-positive stem cells are also positive for at least one of GLP-1 R, ABCG2, integrin subunit α6 and integrin subunit β1;
wherein said nestin-positive stem cells of said population are not neural stem cells,
wherein said population is at least 30% pure; and
wherein said nestin-positive stem cells grow in RPMI-1640 .
2. The population of nestin-positive stem cells of claim 1 , wherein said nestin-positive stem cells are also positive for at least one of the markers selected from the group consisting of Oct3/4, latrophilin (type 2), Hes-1, C-kit, MDR-1, SUR-1, or Kir 6.2.
3. The population of nestin-positive stem cells of claim 1 , wherein said nestin-positive cells do not express at least one of the markers selected from the group consisting of CD34, CD45, CD133, MHC class I and MHC class II.
4. The population of nestin-positive stem cells of claim 1 , wherein said nestin-positive stem cells differentiate to form insulin-producing beta cells.
5. The population of nestin-positive stem cells of claim 1 , wherein said nestin-positive stem cells differentiate to form glucagon-producing alpha cells.
6. The population of nestin-positive stem cells of claim 1 , wherein said nestin-positive stem cells differentiate to form pseudo-islet like aggregates.
7. A pharmaceutical composition comprising nestin-positive stem cell of the population of nestin-positive stem cells of claim 1 admixed with a physiologically compatible carrier.
8. A population of nestin-positive human pancreatic stem cells wherein said nestin-positive stem cells are also positive for at least one of GLP-1 R, ABCG2, integrin subunit α6 and integrin subunit β1;
wherein said nestin-positive stem cells are not neural stem cells;
wherein said stem cell population is at least 40% pure; and
wherein said nestin-positive stem cells grow in RPMI-1640.
9. A population of nestin-positive human pancreatic stem cells that wherein said nestin-positive stem cells are also positive for at least one of GLP-1 R, ABCG2, integrin subunit α6 and integrin subunit β1; wherein said nestin-positive stem cells are not neural stem cells;
wherein said population is at least 50% pure; and
wherein said nestin-positive stem cells grow in RPMI-1640.
10. A population of nestin-positive human pancreatic stem cells wherein said nestin-positive stem cells are also positive for at least one of GLP-1 R, ABCG2;
wherein said nestin-positive stem cells are not neural stem cells;
wherein said population is at least 60% pure; and
wherein said nestin-positive stem cells grow in RPMI-1640.
11. A population of nestin-positive human pancreatic stem cells wherein said nestin-positive stem cells are also positive for at least one of GLP-1 R, ABCG2, integrin subunit α6 and integrin subunit β1;
wherein said nestin-positive stem cells are not neural stem cells;
wherein said population is at least 70% pure; and
wherein said nestin-positive stem cells grow in RPMI-1640.
12. A population of nestin-positive human pancreatic stem cells that wherein said nestin-positive stem cells are also positive for at least one of GLP-1 R, ABCG2, integrin subunit α6 and integrin subunit β1;
wherein said nestin-positive stem cells are not neural stem cells;
wherein said population is at least 80% pure; and
wherein said nestin-positive stem cells grow in RPMI-1640.
13. A population of nestin-positive human pancreatic stem cells wherein said nestin-positive stem cells are also positive for at least one of GLP-1 R or ABCG2, integrin subunit α6 and integrin subunit β1;
wherein said nestin-positive stem cells are not neural stem cells;
wherein said population is at least 85% pure; and
wherein said nestin-positive stem cells grow in RPMI-1640.
14. A population of nestin-positive human pancreatic stem cells wherein said nestin-positive stem cells are also positive for at least one of GLP-1 R or ABCG2, integrin subunit α6 and integrin subunit β1;
wherein said nestin-positive stem cells are not neural stem cells;
wherein said population is at least 90% pure; and
wherein said nestin-positive stem cells grow in RPMI-1640.
15. A population of nestin-positive human pancreatic stem cells wherein said nestin-positive stem cells are also positive for at least one of GLP-1 R, ABCG2, integrin subunit α6 and integrin subunit β1;
wherein said nestin-positive stem cells are not neural stem cells;
wherein said population is at least 95% pure; and
wherein said nestin-positive stem cells grow in RPMI-1640.
16. A population of nestin-positive human pancreatic stem cells wherein said nestin-positive stem cells are also positive for at least one of GLP-1 R, ABCG2, integrin subunit α6 and integrin subunit β1;
wherein said nestin-positive stem cells are not neural stem cells;
wherein said population is at least 98% pure; and
wherein said nestin-positive stem cells grow in RPMI-1640.
17. A population of nestin-positive human pancreatic stem cells wherein said nestin-positive stem cells are also positive for at least one of GLP-1R, ABCG2, integrin subunit α6 and integrin subunit β1;
wherein said nestin-positive stem cells are not neural stem cells;
wherein said population is at least 99% pure; and
wherein said nestin-positive stem cells grow in RPMI-1640.